Slide 1: AI-first discovery platform generating multi-parameter molecules
Sep 10,2025 ev°gene Al-first discovery platform generating multi-parameter molecules REAL-WORLD INNOVATION REAL-WORLD INNOVATION for a better future
Slide 2: Forward Looking Statement
FORWARD LOOKING STATEMENT This presentation contains "forward-looking statements" relating to future events, and Evogene Ltd. (the "Company"), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding o
Slide 3: There is a gap between real-world challenges and innovative solutions
THERE IS A GAP BETWEEN REAL-WORLD CHALLENGES AND INNOVATIVE SOLUTIONS
Slide 4: Utilizing AI and advanced proprietary algorithms to deliver innovative small molecules
UTILIZING Al AND ADVANCED PROPRIETARY ALGORITHMS TO DELIVER INNOVATIVE SMALL MOLECULES, TAILORED TO REAL-WORLD COMMERCIAL PRODUCT NEEDS
Slide 5: We call it: Real-World Innovation
WE CALL IT: REAL-WORLD INNOVATION
Slide 6: Evogene pioneers real-world innovation
EVOGENE PIONEERS REAL-WORLD INNOVATION Using a proprietary generative Al engine, we design highly potent and novel small molecules, optimized across multiple-parameters, for the pharmaceutical and ag-chemical industries
Slide 7: Our story in sentences
OUR STORY IN 3 SENTENCES GEN Al ENGINE REVOLUTIONIZING AG PIONEERING IN PHARMA Design of small molecules with high probability of success Proven results with strategic collaborations Differentiated tech offering that fits market demand
Slide 8: The discovery & optimization challenge
THE DISCOVERY & OPTIMIZATION CHALLENGE DESIGN THE RIGHT CANDIDATES TO REACH THE MARKETDISCOVERY & OPTIMIZATION 1 EARLY ADVANCED APPROVED lc.n DEVELOPMENT DEVELOPMENT PRODUCT LEAD OPTIMIZATIONPHARMA AG | PRECLINICAL | SAFETY & ENVIROMENT CLINICAL FIELD TESTING
Slide 9: Less than 10% of molecules tested in clinical trials make it to market
LESS THAN 10% OF MOLECULES TESTED IN CLINICAL TRIALS MAKE IT TO MARKET Discovery & optimization are the critical stages for increasing market success probability
Slide 10: The multi-parameter optimization challenge
THE MULTI-PARAMETER OPTIMIZATION CHALLENGE Creating a molecule that will succeed through all development phases requires balancing in advance multiple, often competing, parameters THE CHALLENGE FOR TRADITIONAL METHODS: • Optimization typically limited to a small number of parameters • Cannot address
Slide 11: Introducing ChemPass AI: a multi-parameter design engine
INTRODUCING CHEMPASS Al: A MULTI-PARAMETER DESIGN ENGINE FOR REAL-WORLD INNOVATION MULTI-PARAMETER OPTIMIZATION Optimizes multiple-parameters simultaneously, adapted to project specific chemical, biological, and physical constraints, increasing probability of success NOVEL MOLECULAR STRUCTURES Based
Slide 12: ChemPass AI transforms traditional methods
CHEMPASS Al: A MULTI-PARAMETER DESIGN ENGINE FOR REAL-WORLD INNOVATION CHEMPASS Al TRANSFORMS TRADITIONAL METHODS: • Optimization of diverse product specific parameters • Addresses multiple constraints simultaneously • Minimizes lengthy, resource-intensive iterative cycles
Slide 13: Google Cloud x Evogene
Google Cloud Making breakthroughs in life sciences smarter and faster GOOGLE CLOUD x EVOGENE BREAKING NEW GROUND IN AI-FIRST MOLECULE DESIGN TRANSFORMATIVE PARTNERSHIP Combining Evogene's proprietary Al foundation model, with Google Cloud's world-class infrastructure to scale revolutionary molecular
Slide 14: ChemPass AI founded by proprietary technology boosting probability of success
CHEMPASS Al FOUNDED BY PROPRIETARY TECHNOLOGY BOOSTING PROBABILITY OF SUCCESSCHEMPASS Al FOUNDED BY PROPRIETARY TECHNOLOGY BOOSTING PROBABILITY OF SUCCESS
Slide 15: Two strategic market divisions: Pharma and Ag
DELIVERING REAL-WORLD INNOVATION THROUGH TWO STRATEGIC MARKET DIVISIONSPHARMA DIVISION Chem rTassAI AG DIVISION VIAAGPLENUS EXTERNAL COLLABORATIONS oo© Metabolic Disease TEL AVIV UNIVERSITY INTERNAL PIPELINE Undisclosed STRATEGIC COLLABORATION Herbicides ifeCORTEVA Herbicides INTERNAL PIPELINE Wheat
Slide 16: Our story in sentences
OUR STORY IN 3 SENTENCESGEN Al ENGINE REVOLUTIONIZING AG PIONEERING IN PHARMA Proven results with strategic collaborations Differentiated tech offering that fits market demand Design of small molecules with high probability of success
Slide 17: Ag activity via AgPlenus: a growing market
AG ACTIVITY Via AgPlenus A GROWING MARKET WITH PLENTY OF ROOM FOR INNOVATION Increase of pest resistance & regulatory requirements Urgent need for new Modes of Action (MoAs) 3 Decreased rate in discovery of new pesticides due to lack of innovation 17 Company calculation based on: 1) Data Bridge Mark
Slide 18: Computational chemistry can create real-world impact in agriculture
COMPUTATIONAL CHEMISTRY CAN CREATE REAL-WORLD IMPACT IN AGRICULTURE
Slide 19: Strategic collaborations
STRATEGIC COLLABORATIONS"Bringing together AgPlenus' expertise with Bayer's CropKey approach to crop protection innovation will help accelerate the delivery of essential, sustainable, and affordable solutions to farmers and set a new benchmark in the industry." Rachel Rama, Head of Small Molecules,
Slide 20: Internal pipeline: Wheat Blotch
INTERNAL PIPELINE WHEAT BLOTCH DISRUPTING A S1.2B PROBLEM AT RECORD SPEED • 7096 of EU fungicide usage in wheat is for Wheat Blotch1 • EU market alone >$1.2B annually1 • Widespread resistance to current top products ('Strobilurins') with 2024 sales of $4.59B2 APTF-4 PRESENTS STRONG POTENTIAL FOR REA
Slide 21: Our story in sentences
OUR STORY IN 3 SENTENCESGEN Al ENGINE REVOLUTIONIZING AG PIONEERING IN PHARMA Proven results with strategic collaborations Differentiated tech offering that fits market demand Design of small molecules with high probability of success
Slide 22: Pharma division: growing opportunity in AI-drug discovery
PHARMA DIVISION GROWING OPPORTUNITY IN AI-DRUG DISCOVERY Account for 58% Of total pharmaceutical market ($1,344B) Al-based candidates in pipeline >60 150% CAGR in last 3 years Discovery market expected to reach $190.68B by 2034
Slide 23: The discovery and optimization challenge
THE DISCOVERY AND OPTIMIZATION CHALLENGE DEVELOPING CANDIDATES THAT WILL REACH THE MARKET CANDIDATE CUMULATIVE PROBABILITY OF SUCCESS 23 https://pmc.ncbi.nlm.nih.gov/articles/PMC9293739
Slide 24: ChemPass AI: driving higher cumulative probability of success
CHEMPASS Al: DRIVING HIGHER CUMULATIVE PROBABILITY OF SUCCESS PRE-CLINICAL TEST
Slide 25: The key for success: strategic partnerships / internal expertise
THE KEY FOR SUCCESS -STRATEGIC PARTNERSHIPS / INTERNAL EXPERTISE TAILORED TO EACH CHALLENGE & OPTIMIZED FOR SUCCESS PARTNER / INTERNAL EXPERTISELiterature search, data preprocessing and target modeling TARGET PREPROCESSING Identify potential hits using PointHit HIT SCREENING Identify elaborated anal
Slide 26: Showcasing system capabilities: molecular glue case study
SHOWCASING SYSTEM CAPABILITIES: MOLECULAR GLUE CASE STUDY PARTNERSHIP WITH LEADING BIOTECH To develop first-in-class molecular glue therapeutics NOVEL TARGET: Protein-protein interaction, considered highly challenging CHEMPASS Al GENERATED 150 MOLECULES WITH PROMISING RESULTS • 10096 novelty (not in
Slide 27: More real-world innovation in Ag and Pharma means a better world for all
MORE REAL-WORLD INNOVATION IN AG AND PHARMA MEANS A BETTER WORLD FOR ALL
Slide 28: Real-world innovation
REAL-WORLD INNOVATION Unique technology to create novel small molecules MULTI-PARAMETER OPTIMIZATION Balancing ~20 constrains simultaneously using ChemPass Al AI-FIRST, FROM HIT TO LEAD Integrating proprietary technology across the entire discovery pipeline ev°qene Real-world innovation UNLIMITED IN
Slide 29: Real-world innovation for a better future
REAL-WORLD INNOVATION for a better future